 CAMBRIDGE, Mass., July 15, 2021 PRNewswire -- Synlogic, Inc. Nasdaq: SYBX, a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has initiated the Phase 1 clinical trial of SYNB1934, an investigational Synthetic BioticTM medicine for the treatment of Phenylketonuria PKU. 